Floatz logo

FLUTICASONE

Unspecified Adult Solid Tumor, Protocol Specific

Barbara Ann Karmanos Cancer InstituteSmall moleculePhase 2Dormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Unspecified Adult Solid Tumor, Protocol Specific cohort.

Asset / SponsorPhaseRating
NEPENTHE
M.D. Anderson Cancer Center
Phase 4BBB
Amifostine
M.D. Anderson Cancer Center
Phase 4BBB
DEXAMETHASONE
Alliance for Clinical Trials in Oncology
Phase 3BBB
ETOPOSIDE
University of California, Davis
Phase 2/3BBB
Docetaxel
University of Wisconsin, Madison
Phase 2BBB

View all 50 →

Same molecule, other indications

FLUTICASONE is also rated in:

Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic Phase Chronic Myelogenous LeukemiaDormant
BB
Indicative ·
71 / 100
View asset →
Male Breast CancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →